These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11591460)

  • 1. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.
    Wei H; Qin ZH; Senatorov VV; Wei W; Wang Y; Qian Y; Chuang DM
    Neuroscience; 2001; 106(3):603-12. PubMed ID: 11591460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
    Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
    Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.
    Araujo DM; Cherry SR; Tatsukawa KJ; Toyokuni T; Kornblum HI
    Exp Neurol; 2000 Dec; 166(2):287-97. PubMed ID: 11085894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
    Huang Q; Zhou D; Sapp E; Aizawa H; Ge P; Bird ED; Vonsattel JP; DiFiglia M
    Neuroscience; 1995 Mar; 65(2):397-407. PubMed ID: 7777157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.
    Bensadoun JC; de Almeida LP; Dréano M; Aebischer P; Déglon N
    Eur J Neurosci; 2001 Dec; 14(11):1753-61. PubMed ID: 11860469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant treatment protects striatal neurons against excitotoxic insults.
    Nakao N; Grasbon-Frodl EM; Widner H; Brundin P
    Neuroscience; 1996 Jul; 73(1):185-200. PubMed ID: 8783241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
    Araujo DM; Hilt DC
    Neuroscience; 1997 Dec; 81(4):1099-110. PubMed ID: 9330371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala
    Verma MK; Goel R; Nandakumar K; Nemmani KVS
    Eur J Pharmacol; 2018 Jun; 828():31-41. PubMed ID: 29577894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
    Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
    Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease.
    Marco S; Pérez-Navarro E; Tolosa E; Arenas E; Alberch J
    J Neurobiol; 2002 Mar; 50(4):323-32. PubMed ID: 11891666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid.
    Alexi T; Venero JL; Hefti F
    Neuroscience; 1997 May; 78(1):73-86. PubMed ID: 9135090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of dopamine receptors and associated mRNA in transplants of human fetal striatal tissue in rodents with experimental Huntington's disease.
    Pundt LL; Narang N; Kondoh T; Low WC
    Neurosci Res; 1997 Apr; 27(4):305-15. PubMed ID: 9152043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
    Ryu JK; Choi HB; McLarnon JG
    Neuroscience; 2006 Sep; 141(4):1835-48. PubMed ID: 16809003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment.
    Levivier M; Przedborski S
    Neurol Res; 1998 Jan; 20(1):46-56. PubMed ID: 9471103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease.
    Pérez-Navarro E; Canudas AM; Akerund P; Alberch J; Arenas E
    J Neurochem; 2000 Nov; 75(5):2190-9. PubMed ID: 11183872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
    Venero JL; Beck KD; Hefti F
    Neuroscience; 1994 Jul; 61(2):257-68. PubMed ID: 7969907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
    Ryu JK; Kim SU; McLarnon JG
    Exp Neurol; 2004 May; 187(1):150-9. PubMed ID: 15081596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?
    Chuang DM
    Crit Rev Neurobiol; 2004; 16(1-2):83-90. PubMed ID: 15581403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.